Analysis Biomolecular Interactions of Nanobodies17 (Nb17) and Nanobodies (Nb82) to CTNa V 1.4 and CTNa V 1.5 by BLI (CAT#: STEM-MB-0167-CJ)

Introduction

Nanobodies (Nbs) are single variable heavy-chain immunoglobulin domains derived from heavy-chain–only Abs produced in camelids, such as camels, llamas (Lama glama), and alpacas. Nbs are small prolate-shaped molecules (∼15 kDa) that fully retain the epitope-recognizing function in a single-chain Ab. They may be selected to contain an extended and flexible complementarity-determining region 3 (CDR3) loop partly contributing to their high epitope affinity and their ability to better access smaller and cryptic epitopes. Moreover, variable heavy-chain domains are amenable to cloning and protein modifications and can be produced in bacterial expression systems in scalable amounts. Nbs also display superior solubility, stability, in vivo half-lives, and pharmacodynamics compared with conventional Abs. For example, Nbs to P2x channel proteins have been shown to display greater therapeutic potential than conventional Abs for modulating channel function and reducing the in vivo inflammation caused by P2X7. Nbs have also been used as crystallization chaperones, visualization agents, in vivo radiotracers, pulldown baits, intracellular pathway modulators, virus neutralization agents, and therapeutics agents.